Focused radiation for low and intermediate risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a precise type of radiation therapy for early-stage prostate cancer that is normally watched without treatment. The goal is to see if radiation can destroy the cancer while saving healthy tissue and avoiding side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is low or intermediate risk, with a CAPRA score of 5 or less.
- An MRI shows a suspicious spot with a PIRADS score of 4 or higher, and a biopsy of that spot shows cancer.
- Your overall health is good (able to do normal activities), with no major urinary problems.
- You have a PSA level below 20, and no cancer spread outside the prostate.
- You are considered a candidate for active surveillance (watching and waiting).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to deliver high-precision radiation to the prostate using daily MRI or CT scans to adjust the treatment based on your exact anatomy. It aims to make radiation more accurate and reduce side effects.
This trial tests a precise, MRI-guided radiation treatment given over 7 days for people with prostate cancer in specific risk categories. It may help shrink or control the cancer while carefully targeting the tumor.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
This study tests a new radiation treatment approach that uses MRI imaging to target specific tumor areas within the prostate while reducing radiation to healthy tissue. It may help patients with early-stage prostate cancer get effective treatment with fewer side effects.
This trial tests a type of radiation that adjusts to changes in your prostate during treatment. It aims to improve accuracy and reduce side effects for men with intermediate- or high-risk prostate cancer.
Hear when a new Macroscopic Tumor Visualized at MRI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.